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Methyl eugenol [1,2-dimethoxy-4-(2-
propenyl)benzene (CAS no. 93-15-2), struc-
ture shown in Figure 1] is a member of a
family of chemicals known as allyl alkoxy-
benzenes, which include other naturally occur-
ring materials such as isoeugenol, eugenol,
estragole, and safrole. All these compounds
typically enter the diet via a variety of different
food sources, including spices (nutmeg, all-
spice), herbs (basil, tarragon), bananas (Jordan
et al. 2001), and oranges (MacGregor et al.
1974). Many of these compounds are also
found as components of natural oils used in
perfumes (Smith et al. 2002). In addition there
are other potential sources of exposure to
methyl eugenol, including agriculture (Vargas
et al. 2000), consumption of wine (De Simon
et al. 2003), and as part of the ambient back-
ground in air and water (Barr et al. 2000).
Given the broad potential for exposure
resulting from both dietary and consumer
product use and its structural similarity to
other carcinogenic allyl alkoxybenzenes,
methyl eugenol was nominated for study by
the National Toxicology Program (NTP) at
the National Institute of Environmental
Health Sciences. The NTP evaluated methyl
eugenol in a rodent bioassay using oral gavage
as the route of administration (NTP 2000).
Based on the results of the bioassay, the NTP
concluded that there was clear evidence of car-
cinogenicity in F344 rats and B6C3F1 mice.
This conclusion was based on increases in male
and female rats of hepatocellular carcinoma
and hepatocholangiocarcinoma, neuro-
endocrine tumors of the glandular stomach,
and the observation of other tumor types in
several other tissues, and the primary tumors
observed in B6C3F1 mice were hepatocellular
carcinoma in male and female mice and
increased neuroendocrine tumors of the glan-
dular stomach in male mice. Although toxico-
logic end points have been established in
animals, searches of the literature have identi-
ﬁed no clinical studies or epidemiology data to
provide perspective on whether there are
health effects associated with long-term con-
sumption of methyl eugenol by humans.
To provide human exposure data in sup-
port of NTP’s assessment of methyl eugenol,
the Centers for Disease Control and Prevention
(CDC) measured methyl eugenol in a non-
representative subset of adult serum samples 
collected as a part of the Third National
Health and Nutrition Examination Survey
(NHANES III, 1988–1994) (CDC 2004).
The mean serum methyl eugenol concentra-
tion in this subset was approximately 24 pg/g
serum (whole weight), with concentrations
ranging from < 3.1 to 390 pg/g serum (whole
weight) (Barr et al. 2000). The human elimi-
nation kinetics were also evaluated. Volunteers
ingested gingersnap cookies containing a total
of 216 µg methyl eugenol (Schecter et al.
2004). Samples taken after an overnight fast
and before the gingersnap meal had measur-
able levels of methyl eugenol. About 15 min
after ingesting the gingersnaps, the mean con-
centration of methyl eugenol peaked at
54 pg/g serum (whole weight), then fell to a
mean level of about 25 pg/g serum (whole
weight) after 2 hr (Schecter et al. 2004). The
results of this study suggest that low levels of
methyl eugenol are present in the blood after
an oral dose and that the levels rapidly decline.
Because measurements were not made on any
elimination matrices (e.g., urine and feces), it is
not known whether methyl eugenol was
eliminated from the body, stored in distribu-
tion matrices such as adipose tissue, or a com-
bination of the two. Animal studies suggest
that methyl eugenol may be rapidly eliminated
in urine as several metabolites. However, the
presence of methyl eugenol in prefeed human
samples, even after prolonged fasting, suggests
that at least some methyl eugenol may be
stored in distribution matrices that are at equi-
librium with the blood.
Methyl eugenol was presented as a case
study at the September 2004 International
Biomonitoring Workshop (Albertini et al.
2006). Case study excerpts appear in a bio-
monitoring guidance document recently devel-
oped by European Centre for Ecotoxicology
and Toxicology of Chemicals (2005). Here we
present an overview of the current biomonitor-
ing and other relevant data available on expo-
sure to methyl eugenol and the use of these
data in various environmental public health
applications. Methyl eugenol was chosen as a
case study for several reasons. Although human
exposure potential is likely to be high, very
limited human data and animal toxicity data
are available. Furthermore, methyl eugenol is
likely to be a common component of the diet.
These existing data on methyl eugenol are
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Figure 1. Methyl eugenol chemical structure.
O
Oconﬁned to only a few target studies and a rea-
sonably extensive NTP evaluation, albeit at
comparatively high doses administered in bolus
form. Animal toxicity studies indicate carcino-
genicity at every level tested. Regardless, epi-
demiologic studies evaluating similar effects in
humans have not been conducted, even
though their evaluation would be compara-
tively easier than many other environmental
chemicals. This case study illustrates and iden-
tifies some of the data gaps that need to be
filled for the biomonitoring data on methyl
eugenol to be integrated into a risk assessment.
Pharmacokinetics
The human pharmacokinetics of methyl
eugenol are not well defined. Schecter et al.
(2004) reported that methyl eugenol has a
serum half-life in humans of about 90 min.
Little information is available on the human
metabolism of methyl eugenol; however, there
is some suggestion, based on data for estragole,
a structural analogue, that it is similar to that
in animals (Smith et al. 2002). In animals,
methyl eugenol is quickly and completely
absorbed, and the metabolism is regulated 
by dose. Methyl eugenol can undergo
O-demethylation at low doses, and epoxida-
tion or 1´-hydroxylation dominates at higher
doses. A sulfated 1´-hydroxy intermediate that
can undergo rearrangement to form an active
carbonium species is believed to be the biolog-
ically active form of methyl eugenol. This was
initially hypothesized as the species that caused
an increase in unscheduled DNA synthesis
(UDS; Chan and Caldwell 1992). Burkey
et al. (2000) later conﬁrmed this hypothesis by
showing that methyl eugenol–induced UDS
was obviated when cells were treated with pen-
tachlorophenol, an inhibitor that prevented
formation of the sulfated 1´-hydroxy species.
Ultimately, several oxidative metabolites are
excreted in urine, and there is some indication
of conversion to CO2 (Smith et al. 2002).
There is no indication of signiﬁcant accumula-
tion of methyl eugenol in any tissue.
Toxicity Data
The available toxicology data indicate that
methyl eugenol has relatively low acute toxicity
by the oral route, with an acute LD50 (median
lethal dose) in rats of about 1 g/kg (Beroza et al.
1975) and acute percutaneous toxicity (LD50)
of about 2 g/kg in rabbits (Beroza et al. 1975).
There were body weight and hematologic
effects in male and female F344 rats after gav-
age administration of 300 and 1,000 mg
methyl eugenol/kg body weight (NTP 2000)
for 14 weeks. The effects of methyl eugenol
were also evaluated in male and female B6C3F1
mice after gavage administration of doses rang-
ing from 10 to 1,000 mg methyl eugenol/kg
body weight for 14 weeks (NTP 2000). There
was signiﬁcant mortality in the 1,000 mg/kg
groups. The organs affected in the lower-dose
groups included liver, glandular stomach, and
nose (NTP 2000). Based on the results of the
14-week studies, male and female F344 rats and
B6C3F1 mice received oral doses of 0, 37, 75,
or 150 mg/kg/day for 5 days/week for 2 years.
In addition, groups of male and female rats
received 300 mg/kg/day methyl eugenol for
12 months, followed by a 12-month recovery
period. It should be noted that none of the
male rats in the 300-mg/kg/day group survived
to the end of the 2-year study, and 16 of
50 female rats in this group survived to the end
of the study.
The results of the rodent bioassay indicate
that gavage administration of methyl eugenol
resulted primarily in hepatocellular adenomas
and carcinomas in male and female rats and
mice (NTP 2000). There was some increase in
the incidence of tumors in the glandular stom-
ach in male and female rats and male mice
(NTP 2000). In addition, there were increases
in renal tubule adenoma, malignant mesothe-
lioma, mammary gland fibroadenoma, and
subcutaneous fibroma and fibrosarcoma in
male rats (NTP 2000). Importantly, signifi-
cant mortality was reported in the rats given
doses of 150 mg/kg, with the entire male
group dying and half of the female group
dying before the end of the study (NTP
2000). The survival of vehicle control male
and female rats was 40%, which approximates
the historical control mortality for car-
boxymethyl cellulose vehicle. Based on the
high mortality rate for the top-dose male and
female rat treatment groups, it is plausible that
the maximum tolerated dose was exceeded.
Similarly, there was significant mortality
among female mice treated with 150 mg/kg,
with only two animals surviving to the end of
the study compared to 31 female mice in the
vehicle control group (NTP 2000). This
suggests that high-dose female mice also
received treatment that exceeded the maxi-
mum tolerated dose.
The NTP conducted a relatively extensive
series of toxicokinetic studies with methyl
eugenol in rats and mice (NTP 2000). The
results of single-dose gavage administration
studies indicate that maximum plasma concen-
trations were dose dependent and similar for
rats and mice. However, the plasma half-life
was shorter in mice than in rats (NTP 2000).
The results of repeated-dose gavage studies in
rats and mice indicate that methyl eugenol is
rapidly absorbed, with most being eliminated
in the urine, and some suggestion that it is
eliminated more rapidly in mice than in rats
(NTP 2000). Studies with [14C]-labeled
methyl eugenol indicate that the primary organ
for distribution in rats after either oral or intra-
venous administration is the liver (NTP 2000).
The distribution in mice was different, with
signiﬁcant distribution to fat along with several
organs, including liver, spleen, stomach, and
ovaries (NTP 2000). In contrast to the data in
rats, the methyl eugenol distribution in mice
was similar to or greater in fat, spleen, ovary,
and stomach than in liver.
The available genetic toxicology data sug-
gest that methyl eugenol does not have signiﬁ-
cant genotoxic potential. With or without S9
metabolic activation, methyl eugenol was not
mutagenic in Salmonella typhimurium strains
TA98, TA100, TA1535, or TA1537 (NTP
2000). Methyl eugenol, with or without S9
metabolic activation, was not clastogenic when
evaluated in cultured Chinese hamster ovary
cells (NTP 2000), and it was not clastogenic in
the bone marrow of male or female B6C3F1
mice (NTP 2000). One report indicates that
methyl eugenol is cytotoxic to cultured pri-
mary hepatocytes from male F344 rats and
female B6C3F1 mice (Burkey et al. 2000). In
addition methyl eugenol caused a modest
increase in UDS in primary rat and mouse
hepatocytes (Burkey et al. 2000).
Both in vitro and in vivo DNA binding
studies were conducted (Gardner et al. 1997;
NTP 2000). Methyl eugenol, with or without
S9 metabolic activation, was incubated with
calf thymus DNA. The results of the study
indicate that methyl eugenol itself had no
detectable binding to DNA. When S9 from
Arochlor 1254–treated mice or rats was used,
DNA binding was higher than when non-
induced S9 was used. The NTP reported that
human S9 induced less DNA binding than
either rat or mouse S9. Additional studies indi-
cate that methyl eugenol forms DNA adducts
in vivo (NTP 2000) and induces UDS in vivo
(Burkey et al. 2000; Chan and Caldwell 1992;
Gardner et al. 1997; Howes et al. 1990). The
results of these studies support the hypothesis
that the formation of a carbonium ion species
that can react with DNA is the critical metabo-
lite for methyl eugenol exposure. It is impor-
tant to note that Smith et al. (2002) reported
that none of the in vivo DNA adduct studies
has been conducted at doses comparable to
those found in the diet; in fact, the lowest dose
used was about 10 mg/kg/day, which is com-
parable to the doses used in the NTP bioassay.
Biomarker/Analytical Methods
Although several studies have evaluated bio-
markers of methyl eugenol in animals, primar-
ily rats, only one method has been reported to
measure methyl eugenol in humans (Barr et al.
2000). The method used 4 g serum (the equiv-
alent of a 10-mL whole-blood draw) to measure
intact methyl eugenol. Isotopically labeled
methyl eugenol was used as an internal stan-
dard. The methyl eugenol was isolated from the
serum using a general solid-phase extraction
and was measured in the extract using gas chro-
matography/high-resolution mass spectrometry.
Quantification was achieved using isotope
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highly selective and sensitive, a residual contam-
ination in the laboratory air and water made the
analysis difﬁcult. The method had appropriate
sensitivity to measure methyl eugenol in serum,
although the levels were quite low. An added
beneﬁt of measuring methyl eugenol in blood
was the speciﬁcity of the marker for determin-
ing exposure to methyl eugenol itself. The
measurement of metabolites can often be less
selective because common metabolites may be
derived from structurally similar chemicals.
Urinary 1´-hydroxy methyl eugenol and its glu-
curonide-bound analogue are also considered
potential biomarkers for human exposure to
methyl eugenol, although no published meth-
ods exist for its measurement (Smith et al.
2002). Table 1 summarizes the validation
parameters to be considered when evaluating
biomarkers for methyl eugenol.
Exposure Assessment
Limited information exists on speciﬁc sources
of exposure to methyl eugenol. Because it is a
component of many herbs and spices, differ-
ences in dietary habits along with the natural
variation in levels of methyl eugenol in plants
(Di Cesare et al. 2003; Smith et al. 2002)
makes a deﬁnitive prediction of exposure difﬁ-
cult. Based on known levels in foods, spices,
and herbs, the Flavor Extract Manufacturers
Association (FEMA) estimated that methyl
eugenol consumption from food is about
5–6 µg/kg/day (Smith et al. 2002). The FEMA
group assumed that the top 10% of people con-
suming methyl eugenol consumed all of the
methyl eugenol in commerce (Smith et al.
2002). In addition, use of essential oils as ﬂa-
voring agents has resulted in a total methyl
eugenol exposure of no more than about
10 µg/kg/day. However, ethnic or cultural
dietary habits may result in substantially higher
exposures to methyl eugenol; one estimate indi-
cates as much as 250 µg methyl eugenol/
kg/meal from a pesto meal (Miele et al. 2001).
The integrated exposure to methyl eugenol
derived from the biomonitoring data indicates
that serum levels have been measured as high
as 390 pg/g and may be higher in some indi-
viduals depending on diet, genetics, body
weight, and so forth (Barr et al. 2000; Schecter
et al. 2004). The highest blood levels after con-
sumption of about 216 µg of methyl eugenol
in contained in gingersnap cookies was about
100 pg/g or 3.16 µg/kg (Schecter et al. 2004).
These data and the highest level reported in
the biomonitoring study (Barr et al. 2000)
translate to exposures ranging from about
4–12 µg/kg/day, which is very similar to the
estimates presented by Smith et al. (2002).
Although exposure estimates based on the bio-
monitoring data are similar to those derived
from food consumption, it should be noted
that the biomonitoring data were derived from
a subset of the general population and that
population sampling did not account for
dietary or other lifestyle factors that could
inﬂuence methyl eugenol serum levels. This is
supported by the fact that the highest serum
levels in fasting individuals who consumed
cookies containing methyl eugenol was only
about one-fourth that of the highest serum lev-
els reported in the NHANES population (Barr
et al. 2000; Schecter et al. 2004). The fact that
methyl eugenol has a relatively short half-life
and that data regarding when food was con-
sumed relative to when blood samples were
collected from the NHANES subjects make it
difficult to determine whether a steady-state
was reached. This clearly highlights the need
for both dietary information and temporal
information when samples are collected.
Furthermore, collection of multiple samples
over relatively short periods of time would pro-
vide important additional data to help in the
development of a human pharmacokinetic
model. Development of a human pharmaco-
kinetic model would be valuable for comparing
the rodent toxicology data to human exposure.
This could be further augmented with sample
collection over longer intervals that, when cou-
pled with the NHANES demographic infor-
mation, would provide perspective on ethnic,
gender, and/or racial exposure trends.
Biomonitoring/
Risk Assessment
Although no link between methyl eugenol con-
sumption and health effects in humans has
been identified, in part because of a limited
number of studies in humans and an absence of
epidemiology data, it is worthwhile to compare
human exposure based on biomonitoring data
to the available rodent bioassay data. A recent
study provided some information regarding the
pharmacokinetics of methyl eugenol in humans
(Schecter et al. 2004). Volunteers consumed
gingersnap cookies containing approximately
18 µg methyl eugenol per cookie, resulting in a
total consumption of about 216 µg of methyl
eugenol. The level of methyl eugenol in the
blood peaked at about 15 min, and the half-life
was estimated to be about 2 hr (Schecter et al.
2004). The highest exposure estimated from
the Barr et al. (2000) study is as much as 4-fold
greater than the highest exposure in the ginger-
snap study (Schecter et al. 2004).
In contrast to the relatively low-dose expo-
sures in humans, the lowest dose used in the
2-year rodent studies was 37,000 µg/kg/day.
Thus, human dietary exposures are substantially
lower than the lowest dose used in the NTP
study. Even the high-consumption single-meal
dose of about 250 µg methyl eugenol/kg (Miele
et al. 2001) is almost 150-fold lower than the
lowest dose used in the NTP study. It is impor-
tant to note that the methyl eugenol biomoni-
toring data offer a starting point for examining
the risk assessment paradigm as it applies to
cancer risk assessment. Although the NTP
rodent bioassay study design was intended pri-
marily as a hazard identiﬁcation tool, the results
of such studies are often used to develop quan-
titative potency estimates for risk assessment. A
number of different extrapolation methods
have been developed and are used by state agen-
cies such as the Ofﬁce of Environmental Health
Hazard Assessment in California, national
agencies such as the U.S. Environmental
Protection Agency, and international agencies
such as the European Union and Health
Canada for regulatory decision making.
Typically for cancer risk assessment, linear
extrapolation methods are used to derive a
quantitative cancer risk or potency estimate,
resulting in very low numerical values. Based on
dietary consumption alone, it is likely that
methyl eugenol exposure exceeds quantitative
cancer potency estimates derived by linear
extrapolation methods by several orders of mag-
nitude. The exposure estimates outlined by
Schecter et al. (2004) indicate that rodents had
an increased liver cancer risk in the range of
17–50%. The authors indicated that human
exposures would be about 10,000-fold lower
than the exposures in the rodent bioassay.
Although the projected dietary exposure is
lower than the doses used in the rodent bio-
assay, direct comparison is complicated because
the animals received gavage doses as opposed to
dietary administration, and there are no bio-
monitoring data in rodents after dietary con-
sumption of methyl eugenol.
Conclusions and
Recommendations
Hazard identiﬁcation data indicate that methyl
eugenol induces hepatocellular carcinomas
along with tumors at several other sites in 
rats and hepatocellular carcinoma in mice.
Biomonitoring and methyl eugenol
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Table 1. Evaluation of biomarkers for methyl eugenol.
Validation parameter ME 1-OH-ME
Speciﬁcity of marker for exposure Most speciﬁc Most speciﬁc
Matrix for measurement Blood Blood
Alternative exposures that may result in presence of biomarker in matrix None None
Speciﬁcity of marker for predicting health outcome Nonspeciﬁc Nonspeciﬁc
Stability of marker in matrix Very stable Very stable
Data from multiple laboratories No No
Interlaboratory comparison No No
Abbreviations: ME, methyl eugenol; 1´-OH-ME, 1´-hydroxy methyl eugenol.However, the relevance of these results remains
in question. The animals received substantial
bolus doses that are not representative of typi-
cal methyl eugenol exposure. Relatively high
doses of methyl eugenol that overwhelm the
most common metabolic pathways have been
suggested as the mechanism resulting in the
formation of a reactive carbonium ion from
the 1´-hydroxymethyl eugenol metabolite
(Gardner et al. 1997; Rietjens et. al. 2005;
Smith et al. 2002). This raises the possibility
that a 1´-hydroxyl reactive metabolite is not
formed at signiﬁcant levels at lower exposures.
It is important to note that given the lack of
clinical or epidemiology data, there is no way
to determine an association between human
exposure to methyl eugenol and disease.
Conducting human epidemiology studies to
evaluate the association of diets containing a
high level of methyl eugenol and any type of
health outcome would provide valuable per-
spective. This clearly highlights the need for
additional human data and the need to modify
toxicology studies to include biomonitoring
end points. The availability of biomonitoring
data in humans and rodents after dietary con-
sumption/low-dose exposure would greatly
facilitate the integration of biomonitoring data
into the risk assessment.
The potential for the formation of a reac-
tive metabolite at high exposures as noted
above suggests that more than one biomarker
could be measured. The methyl eugenol bio-
monitoring data are based on detection of the
parent compound in serum (Barr et al. 2000).
Reports in the literature indicate a threshold
for methyl eugenol tumor induction in rats
(Waddell 2002). In addition Waddell et al.
(2004) report that DNA adduct formation
correlates with tumor induction in rats. The
existing data support the conclusion that lower
doses of methyl eugenol and other allyl alkoxy-
benzenes undergo O-demethylation as the pri-
mary route of detoxiﬁcation. This is supported
by the report that microsomes from the livers
of rats administered methyl eugenol at doses of
30–300 mg mg/kg autoinduced 1´-hydroxyla-
tion of methyl eugenol, whereas those of rats
administered 10 mg/kg did not (Gardner et al.
1997). With relatively low (dietary) doses, it is
likely that very little of the 1´-hydroxyl
metabolite is formed; however, as doses
increase, a shift in metabolism to this pathway
occurs (Smith et al. 2002). Formation of the
1´-hydroxyl metabolite is particularly impor-
tant because it is thought to form a carbonium
ion that results in a reactive intermediate mol-
ecule (Burkey et al. 2000; Smith et al. 2002).
Because the possibility of different metabolic
pathways has been raised, additional perspec-
tive could be gained from biomonitoring 
the formation of the 1´-hydroxy and other
metabolites at different doses, including com-
parisons of lower and higher doses of methyl
eugenol. This type of information would help
determine whether there is induction of a
metabolic shift and would offer additional sup-
port for a threshold for methyl eugenol–
induced effects, if a signiﬁcant quantity of the
reactive intermediate is formed only at higher
doses.
The toxicokinetics of methyl eugenol after
gavage have been reasonably well studied in
animals, and a physiologically based pharmaco-
kinetic model exists (NTP 2000). These data
indicate that methyl eugenol is rapidly
absorbed, metabolized, and excreted after bolus
administration. There is one report that
cytochrome P450 (CYP) E1 is responsible for
1´-hydroxylation in the rat (Gardner et al.
1997). For humans, there is some good pre-
liminary information on the absorption and
elimination of methyl eugenol (Schecter et al.
2004). The results of this study indicate that
humans also rapidly absorb and eliminate
methyl eugenol. However, only one dose was
administered to a relatively small number of
subjects. Obtaining additional data to develop
a human physiologically based pharmaco-
kinetic model would provide a tool for com-
parison and aid the interpretation of the rodent
toxicity data. Recently, it has been reported
that human CYP1A2 is responsible for
1´-hydroxylation at dietary concentrations and
that CYP2C9, CYP2C19, and CYP2D6 par-
ticipate at higher concentrations (Jeurissen
et al. 2006). This further supports that there
are distinct differences in the formation of the
reactive metabolite at lower methyl eugenol
exposures. In addition it suggests that there
may be fundamental differences in the metabo-
lism of methyl eugenol between rodents and
humans. Because a single cytochrome P450 in
humans appears to be primarily responsible for
metabolism at low doses of methyl eugenol, it
also raises the question of population hetero-
geneity. This highlights the need for obtaining
additional metabolism and pharmacokinetic
data in humans so that appropriate compar-
isons can be made to the existing animal data.
Finally, another important consideration is
that the rodent bioassay was conducted using
oral gavage as a means of administering
methyl eugenol. There is limited relevance of
oral gavage dosing for a material that is con-
sumed at much lower levels in the diet. This
has the net effect of presenting the animal
with a large bolus dose of material that, as dis-
cussed above, may overwhelm detoxification
pathways. The primary source of human
exposure to methyl eugenol is most likely the
diet. This would represent relatively low-level
exposure that is likely to be well within both
animal and human metabolic capacity.
Evaluating the impact of route by administer-
ing methyl eugenol in the diet of rats and mice
would add important information to our
understanding of chronic dietary exposure to
methyl eugenol. Tissue collection for biomon-
itoring information and determination of
DNA adducts in the treated animals are
included in the protocol. There should also be
some consideration of gathering pharmaco-
kinetic data after dietary administration
because the existing data were gathered after
gavage or intravenous administration.
This evaluation of methyl eugenol illus-
trates some of the questions that should 
be asked when attempting to integrate bio-
monitoring into risk assessment. It also high-
lights some of the data gaps that need to be
filled to develop a risk assessment of methyl
eugenol. Although there are a number of toxi-
cology studies in animals, questions remain un-
answered regarding the relevance of oral gavage
administration of high-bolus doses used in the
NTP studies, relative to the much lower doses
received after dietary consumption of foods
containing methyl eugenol. Recently there is
some suggestion of a difference in metabolism
of methyl eugenol between humans and
rodents, and that significant amounts of the
hypothesized critical metabolite occur at rela-
tively high concentrations. Limited toxico-
kinetic data in humans exist, and there may be
differences in the primary detoxiﬁcation path-
ways; additional toxicokinetic data are needed
to gain a better understanding. This is particu-
larly important because the 1´-hydroxy path-
way is responsible for formation of the reactive
carbonium ion. Furthermore, although there
are very limited human health and no epidemi-
ology data, no adverse human health effects
have been associated with dietary consumption
of methyl eugenol.
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